Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Escalation Study of IG3018 to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics in Subjects With Hyperuricemia With or Without Chronic Kidney Disease

NCT06310967 is registered in ClinicalTrials.gov with Intelligem Therapeutics Australia Pty Ltd. as lead sponsor.

NCT NCT06310967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06310967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Escalation Study of IG3018 to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics in Subjects With Hyperuricemia With or Without Chronic Kidney Disease
Lead sponsor
Intelligem Therapeutics Australia Pty Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 12, 2024
Completion date
January 31, 2027
Enrollment
60 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hyperuricemia, hypouricemia, renal